Cohn J N, Tognoni G, Glazer R, Spormann D
University of Minnesota Medical School, Box 508, 420 Delaware Street S.E., Minneapolis, MN 55455, USA.
Eur J Heart Fail. 2000 Dec;2(4):439-46. doi: 10.1016/s1388-9842(00)00130-6.
The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in heart failure patients. A total of 5010 patients with an ejection fraction <40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo.
Baseline characteristics of patients in Val-HeFT are presented and compared with other major clinical trials in heart failure.
Baseline data were collected and summary statistics calculated.
The study population has a mean age of 62.7 years and is 80% male, 90.3% white, 6.9% black, and 2.8% Asian. Antecedent coronary heart disease is reported in 57.2% of patients. Angiotensin-converting enzyme inhibitors are prescribed for 92.7% of patients, diuretics for 85.8%, digoxin for 67.3%, and beta-blockers for 35.6%. Subgroup comparisons by age, sex, race and ejection fraction quartile show small differences in baseline characteristics.
Overall the Val-HeFT population is generally representative of the population of patients with mild to moderate heart failure in industrialized countries.
缬沙坦心力衰竭试验（Val-HeFT）是第一项大规模、随机、多国临床研究，旨在评估在心力衰竭患者中，在包括血管紧张素转换酶抑制剂在内的传统治疗基础上加用血管紧张素II受体阻滞剂缬沙坦的疗效和安全性。共有5010例射血分数<40%的患者被随机分为接受滴定至160mg每日两次的缬沙坦治疗或接受安慰剂治疗。
介绍Val-HeFT研究中患者的基线特征，并与其他主要的心力衰竭临床试验进行比较。
收集基线数据并计算汇总统计量。
研究人群的平均年龄为62.7岁，男性占80%，白人占90.3%，黑人占6.9%，亚洲人占2.8%。57.2%的患者有既往冠心病史。92.7%的患者使用血管紧张素转换酶抑制剂，85.8%的患者使用利尿剂，67.3%的患者使用地高辛，35.6%的患者使用β受体阻滞剂。按年龄、性别、种族和射血分数四分位数进行的亚组比较显示，基线特征存在微小差异。
总体而言，Val-HeFT研究人群一般代表了工业化国家中轻至中度心力衰竭患者群体。
